|
|
Volumn 366, Issue 4, 2012, Pages 379-380
|
|
Briakinumab versus methotrexate for psoriasis [1]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTINUCLEAR ANTIBODY;
BRIAKINUMAB;
DRUG ANTIBODY;
METHOTREXATE;
MONOCLONAL ANTIBODY;
DERMATOLOGICAL AGENT;
AUTOIMMUNE DISEASE;
CLINICAL PROTOCOL;
COMPARATIVE EFFECTIVENESS;
DISEASE SEVERITY;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
IMMUNOGENICITY;
INFECTION;
LETTER;
NEOPLASM;
PRIORITY JOURNAL;
PSORIASIS;
RISK ASSESSMENT;
RISK FACTOR;
FEMALE;
MALE;
NOTE;
ANTIBODIES, MONOCLONAL;
DERMATOLOGIC AGENTS;
FEMALE;
HUMANS;
MALE;
METHOTREXATE;
PSORIASIS;
|
|
EID: 84856242108
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1113864 Document Type: Letter |
|
Times cited : (4)
|
|
References (3)
|
